Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
7Customers
2Debt Items
12Related Chains
Source-Backed Evidence Depth
Coya Therapeutics, Inc. (COYA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
4Distinct source URLs
10High confidence
0.819Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Coya Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
92%
The Company has agreed to pay Leerink Partners a commission of 3.0% of the aggregate gross proceeds from any Placement Shares sold by Leerink Partners
ARS
ARS
90%
In consideration for the ARS Option, we paid ARS a one-time, non-refundable, non-creditable option fee of $0.1 million.
DRL
DRL
90%
In consideration for the license, we paid a non-refundable upfront fee of $0.4 million.
THE-METHODIST-HOSPITAL
THE-METHODIST-HOSPITAL
85%
As part of the Methodist License Agreement, we will pay Methodist a four-figure license maintenance fee annually until the first sale of licensed product occurs.
Coya Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
92%
The Company may offer and sell, from time to time through or to Leerink Partners, shares of the Company’s common stock
DR-REDDY-S-LABS
DR-REDDY-S-LABS
90%
The Purchasers in the Offering are Dr. Reddy’s Labs ($10.0 million) and Greenlight Capital ($1.1 million), an existing institutional stockholder of the Company.
GREENLIGHT-CAPITAL
GREENLIGHT-CAPITAL
90%
The Purchasers in the Offering are Dr. Reddy’s Labs ($10.0 million) and Greenlight Capital ($1.1 million), an existing institutional stockholder of the Company.
ARSCIENCE-BIOTHERAPEUTICS-INC
ARSCIENCE-BIOTHERAPEUTICS-INC
62%
ments for clinical trials and potential commercialization; • establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional comme…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
rch 96,250 202,410 Internal costs: Internal research and development expenses, including stock-based compensation 1,198,440 989,290 Total $ 4,096,580 $ 5,214,076 25 General and Administrative Expense…
DR-REDDY-S-LABORATORIES-LTD
DR-REDDY-S-LABORATORIES-LTD
62%
f October 2030. 77 In January of 2026, we entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,522,727 shares of our co…
Reciprocal relationship from RDY graph: Reciprocal relationship from COYA graph: Reciprocal relationship from RDY graph: Reciprocal relationship from COYA graph: Reciprocal relationship from RDY grap…
Coya Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
COYA-DEBT-8811
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
COYA-DEBT-8810
Warrants outstanding: 2141128
90%
xbrl warrant detail from xbrl 2024-12-31.
Coya Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Coya Therapeutics, Inc..
Coya Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
COYA-OWNER-DME-CAPITAL-MANAGEMENT-LP
DME Capital Management, LP
90%
13F overlay lists DME Capital Management, LP as top holder; 57 tracked holders.
Coya Therapeutics, Inc. Extended Supply Chain Network
